Chromadex (CDXC)

Company Profile

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®.

Company profile

Ticker

CDXC

Exchange

NASDAQ

Website

www.chromadex.com

CEO

Robert Fried

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Medicinal and Botanical Manufacturing

Industry (SIC)

Medicinal Chemicals & Botanical Products

Jushi • Ascend Wellness • Trulieve Cannabis • Usana Health Sciences • 4Front Ventures • SNDL • Mind Medicine • Glass House Brands • C21 Investments • Tilray Brands ...

Former names

CODY RESOURCES, INC.

SEC CIK

0001386570

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

ChromaDex, Inc. • ChromaDex International, Inc. • ChromaDex Analytics, Inc. • ChromaDex Europa B.V. • ChromaDex UK Limited • Asia Pacific Scientific, Inc. • ChromaDex Asia Limited • ChromaDex Asia Pacific Ventures Limited • ChromaDex Trading (Shanghai) Co., Ltd. ...

IRS number

262940963

CDXC stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

5 Jan 23

424B3

Prospectus supplement

17 Nov 22

EFFECT

Notice of effectiveness

17 Nov 22

CORRESP

Correspondence with SEC

2 Nov 22

ChromaDex Corporation Reports Third Quarter 2022 Financial Results

2 Nov 22

$3.10 mm in equity, sold $3.10 mm, 3 investors

14 Oct 22

424B5

Prospectus supplement for primary offering

11 Oct 22

Transcripts

View all

CDXC

Earnings call transcript

2022 Q2

11 Aug 22

CDXC

Earnings call transcript

2022 Q1

13 May 22

CDXC

Earnings call transcript

2021 Q4

10 Mar 22

CDXC

Earnings call transcript

2021 Q3

4 Nov 21

CDXC

Earnings call transcript

2021 Q2

4 Aug 21

CDXC

Earnings call transcript

2021 Q1

9 May 21

CDXC

Earnings call transcript

2020 Q4

11 Mar 21

CDXC

Earnings call transcript

2020 Q3

4 Nov 20

CDXC

Earnings call transcript

2020 Q2

9 Aug 20

CDXC

Earnings call transcript

2020 Q1

11 May 20

Latest ownership filings

View all

SC 13G

Societe des Produits Nestle S.A.

19 Oct 22

Robert N Fried

3 Oct 22

Hoi Shuen Solina Holly Chau

Champion River Ventures Ltd

3 Oct 22

SC 13D/A

Pioneer Step Holdings Ltd

Financial summary

Financial statements Chart CDXC financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	13.26 mm	13.26 mm	13.26 mm	13.26 mm	13.26 mm	13.26 mm
Cash burn (monthly)	1.27 mm	1.65 mm	1.02 mm	1.88 mm	1.25 mm	1.64 mm
Cash used (since last report)	5.34 mm	6.95 mm	4.30 mm	7.88 mm	5.24 mm	6.91 mm
Cash remaining	7.92 mm	6.31 mm	8.97 mm	5.38 mm	8.02 mm	6.36 mm
Runway (months of cash)	6.2	3.8	8.8	2.9	6.4	3.9

Beta Read what these cash burn values mean

Financial data from Chromadex earnings reports.

Institutional ownership, Q3 2022

CDXC institutional ownership history Ownership history

59.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	63	79	-20.3%
Opened positions	4	16	-75.0%
Closed positions	20	24	-16.7%
Increased positions	10	21	-52.4%
Reduced positions	25	25	–

13F shares	Current	Prev Q	Change
Total value	108.03 mm	117.21 mm	-7.8%
Total shares	44.05 mm	38.28 mm	+15.1%
Total puts	0.00	22.10 k	EXIT
Total calls	38.40 k	35.50 k	+8.2%
Total put/call ratio	–	0.6	–

Largest owners	Shares	Value	Change
Champion River Ventures	7.94 mm	$9.77 mm	NEW
Pioneer Step	6.92 mm	$8.51 mm	+16.1%
Shing Li Ka	6.50 mm	$11.44 mm	0.0%
Hoi Shuen Solina Holly Chau	5.96 mm	$38.73 mm	0.0%
Li Ka Shing	3.47 mm	$12.97 mm	0.0%
Tieton Capital Management	2.28 mm	$2.80 mm	-0.4%
Vanguard	2.23 mm	$2.74 mm	+2.2%
Yong Rong	1.93 mm	$2.38 mm	-28.6%
ICONIQ Capital	1.30 mm	$1.60 mm	0.0%
Phillip MD Frost Et Al	1.23 mm	$11.82 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Champion River Ventures	7.94 mm	+7.94 mm	NEW
Pioneer Step	6.92 mm	+960.00 k	+16.1%
Yong Rong	1.93 mm	-776.00 k	-28.6%
Millennium Management	200.66 k	-562.93 k	-73.7%
Citadel Advisors	56.57 k	-316.99 k	-84.9%
GS Goldman Sachs	13.36 k	-309.71 k	-95.9%
STT State Street	0.00	-237.10 k	EXIT
Aqr Capital Management	76.57 k	-156.23 k	-67.1%
Susquehanna International	95.62 k	-145.01 k	-60.3%
MS Morgan Stanley	25.41 k	-129.87 k	-83.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CDXC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Sep 22	Hoi Shuen Solina Holly Chau	Common Stock	Buy	Acquire P	Yes	No	1.25	960,000	1.20 mm	7,885,641
30 Sep 22	Fried Robert N	Common Stock	Buy	Acquire P	No	No	1.25	80,000	100.00 k	972,314
12 Aug 22	Brianna Gerber	RSU Common Stock	Grant	Acquire A	No	No	0	67,308	0.00	67,308
12 Aug 22	Brianna Gerber	Employee Stock Options Common Stock	Grant	Acquire A	No	No	1.69	100,460	169.78 k	100,460
12 Aug 22	Farr Kevin M	RSU Common Stock	Grant	Acquire A	No	No	0	89,189	0.00	89,189